Invitrogen™ Bcl-2 Recombinant Rabbit Monoclonal Antibody (204), FITC

Description

Preparation: This antibody was obtained from a rabbit immunized with a synthetic peptide corresponding to the N-terminus of the Human Bcl-2, and it was conjugated with FITC under optimum conditions, the unreacted FITC was removed. Storage: This antibody can be stored at 2C-8C for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze! Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

BCL-2 is a key regulator of apoptosis that functions to either inhibit or promote cell death. The BCL-2 family members are also characterized by dimerizing to further modulate apoptosis. Bag1, for example, has been found to form a heterodimer with BCL-2 resulting in the enhancement of the anti-apoptotic effect of BCL-2. Bax and Bak have been shown to play a critical role in cytochrome c release from mitochondria and thus initiate apoptosis. Bax exerts a pro-apoptotic rather than an anti-apoptotic effect on cells. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. In most follicular lymphomas, neoplastic germinal centers express high levels of BCL-2 alpha protein, whereas the normal or hyperplastic germinal centers are negative. Two transcript variants of BCL-2, produced by alternate splicing, differ in their C-terminal ends. The overexpression of BCL-2 has been linked to human cancers such as B-cell lymphoma and prostate cancer.